Anti-angiogenic potential of an ethanol extract of Annona atemoya seeds in vitro and in vivo

详细信息    查看全文

• 作者：Jin-Mu Yi (14) (16)
  Jong-Shik Park (14)
  Jun Lee (14)
  Jin Tae Hong (16)
  Ok-Sun Bang (14)
  No Soo Kim (14) (15)
  
  14. KM-Based Herbal Drug Development Group ; Korea Institute of Oriental Medicine ; 1672 Yuseong-daero ; Yuseong-gu ; Daejeon ; 305-811 ; Republic of Korea
  16. College of Pharmacy ; Chungbuk National University ; Cheongju ; Republic of Korea
  15. Department of Korean Medicine Life Science and Technology ; Korea University of Science and Technology ; Daejeon ; Republic of Korea
  
• 关键词：Annona atemoya ; Angiogenesis ; Anticancer ; HIF ; VEGF
• 刊名：BMC Complementary and Alternative Medicine
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：1,057 KB
• 参考文献：1. Birbrair, A, Zhang, T, Wang, ZM, Messi, ML, Olson, JD, Mintz, A, Delbono, O (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 307: pp. C25-C38 CrossRef
  2. Flamme, I, Frolich, T, Risau, W (1997) Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 173: pp. 206-210 CrossRef
  3. Jang, YJ, Kim, DS, Jeon, OH, Kim, DS (2007) Saxatilin suppresses tumor-induced angiogenesis by regulating VEGF expression in NCI-H460 human lung cancer cells. J Biochem Mol Biol 40: pp. 439-443 CrossRef
  4. Matsunaga, N, Chikaraishi, Y, Shimazawa, M, Yokota, S, Hara, H (2010) Vaccinium myrtillus (Bilberry) extracts reduce angiogenesis in vitro and in vivo. Evid Based Complement Alternat Med: eCAM 7: pp. 47-56 CrossRef
  5. Papetti, M, Herman, IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: pp. C947-C970 CrossRef
  6. Tosetti, F, Ferrari, N, De Flora, S, Albini, A (2002) Angioprevention鈥? angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16: pp. 2-14 CrossRef
  7. Tandle, A, Blazer, DG, Libutti, SK (2004) Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2: pp. 22 CrossRef
  8. Huang, TF, Yeh, CH, Wu, WB (2001) Viper venom components affecting angiogenesis. Haemostasis 31: pp. 192-206
  9. Folkman, J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: pp. 1182-1186 CrossRef
  10. Seffrin, RD, Shikano, I, Akhtar, Y, Isman, MB (2010) Effects of crude seed extracts of Annona atemoya and Annona squamosa L. against the cabbage looper, Trichoplusia ni in the laboratory and greenhouse. Crop Prot 29: pp. 20-24 CrossRef
  11. Tiangda, CH, Gritsanapan, W, Sookvanichsilp, N, Limchalearn, A (2000) Anti-headlice activity of a preparation of Annona squamosa seed extract. Southeast Asian J Trop Med Public Health 31: pp. 174-177
  12. Leatemia, JA, Isman, MB (2004) Efficacy of crude seed extracts of Annona squamosa against diamondback moth, Plutella xylostella L. in the greenhouse. Int J Pest Manage 50: pp. 129-133 CrossRef
  13. Leatemia, JA, Isman, MB (2004) Insecticidal activity of crude seed extracts of Annona spp., Lansium domesticum and Sandoricum koetjape against lepidopteran larvae. Phytoparasitica 32: pp. 30-37 CrossRef
  14. Chih, HW, Chiu, HF, Tang, KS, Chang, FR, Wu, YC (2001) Bullatacin, a potent antitumor annonaceous acetogenin, inhibits proliferation of human hepatocarcinoma cell line 2.2.15 by apoptosis induction. Life Sci 69: pp. 1321-1331 CrossRef
  15. Chiu, HF, Chih, TT, Hsian, YM, Tseng, CH, Wu, MJ, Wu, YC (2003) Bullatacin, a potent antitumor Annonaceous acetogenin, induces apoptosis through a reduction of intracellular cAMP and cGMP levels in human hepatoma 2.2.15 cells. Biochem Pharmacol 65: pp. 319-327 CrossRef
  16. Fu, LW, He, LR, Liang, YJ, Chen, LM, Xiong, HY, Yang, XP, Pan, QC (2003) Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89鈥?. Yao xue xue bao = Acta pharmaceutica Sinica 38: pp. 565-570
  17. Yi, JM, Park, JS, Oh, SM, Lee, J, Kim, J, Oh, DS, Bang, OS, Kim, NS (2012) Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo. BMC Complement Altern Med 12: pp. 243 CrossRef
  18. Keith, B, Johnson, RS, Simon, MC (2012) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: pp. 9-22
  19. Semenza, GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: pp. 721-732 CrossRef
  20. Harris, AL (2002) Hypoxia鈥揳 key regulatory factor in tumour growth. Nat Rev Cancer 2: pp. 38-47 CrossRef
  21. Kumaran, G, Clamp, AR, Jayson, GC (2008) Angiogenesis as a therapeutic target in cancer. Clin Med 8: pp. 455-458 CrossRef
  22. Zihlif, M, Afifi, F, Abu-Dahab, R, Abdul Majid, AM, Somrain, H, Saleh, MM, Nassar, ZD, Naffa, R (2013) The antiangiogenic activities of ethanolic crude extracts of four Salvia species. BMC Complement Altern Med 13: pp. 358 CrossRef
  23. Risau, W (1997) Mechanisms of angiogenesis. Nature 386: pp. 671-674 CrossRef
  24. Mabjeesh, NJ, Post, DE, Willard, MT, Kaur, B, Van Meir, EG, Simons, JW, Zhong, H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62: pp. 2478-2482
  25. Zundel, W, Schindler, C, Haas-Kogan, D, Koong, A, Kaper, F, Chen, E, Gottschalk, AR, Ryan, HE, Johnson, RS, Jefferson, AB, Stokoe, D, Giaccia, AJ (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: pp. 391-396
  26. Jiang, BH, Jiang, G, Zheng, JZ, Lu, Z, Hunter, T, Vogt, PK (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: pp. 363-369
  27. Kirkpatrick, DL, Kuperus, M, Dowdeswell, M, Potier, N, Donald, LJ, Kunkel, M, Berggren, M, Angulo, M, Powis, G (1998) Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 55: pp. 987-994 CrossRef
  28. Welsh, SJ, Williams, RR, Birmingham, A, Newman, DJ, Kirkpatrick, DL, Powis, G (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2: pp. 235-243
  29. Chen, B, Yuping, S, Ni, J (2012) Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1alpha induction. Mol Biol Rep 39: pp. 185-191 CrossRef
  30. Chun, YS, Yeo, EJ, Choi, E, Teng, CM, Bae, JM, Kim, MS, Park, JW (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61: pp. 947-954 CrossRef
  31. Li, SH, Shin, DH, Chun, YS, Lee, MK, Kim, MS, Park, JW (2008) A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther 7: pp. 3729-3738 CrossRef
  32. Lau, CK, Yang, ZF, Lam, CT, Tam, KH, Poon, RT, Fan, ST (2006) Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 348: pp. 1443-1448 CrossRef
  33. Oh, SH, Woo, JK, Jin, Q, Kang, HJ, Jeong, JW, Kim, KW, Hong, WK, Lee, HY (2008) Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 122: pp. 5-14 CrossRef
  34. Forsythe, JA, Jiang, BH, Iyer, NV, Agani, F, Leung, SW, Koos, RD, Semenza, GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: pp. 4604-4613
  35. Isaacs, JS, Jung, YJ, Mimnaugh, EG, Martinez, A, Cuttitta, F, Neckers, LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: pp. 29936-29944 CrossRef
  36. Eguchi, H, Ikuta, T, Tachibana, T, Yoneda, Y, Kawajiri, K (1997) A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor 1beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex. J Biol Chem 272: pp. 17640-17647 CrossRef
  37. Wang, GL, Jiang, BH, Rue, EA, Semenza, GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: pp. 5510-5514 CrossRef
  38. Chen, Y, Xu, SS, Chen, JW, Wang, Y, Xu, HQ, Fan, NB, Li, X (2012) Anti-tumor activity of Annona squamosa seeds extract containing annonaceous acetogenin compounds. J Ethnopharmacol 142: pp. 462-466 CrossRef
  39. Vila-Nova, NS, Morais, SM, Falcao, MJ, Machado, LK, Bevilaqua, CM, Costa, IR, Brasil, NV, Andrade Junior, HF (2011) Leishmanicidal activity and cytotoxicity of compounds from two Annonacea species cultivated in Northeastern Brazil. Rev Soc Bras Med Trop 44: pp. 567-571 CrossRef
  40. Wele, A, Zhang, Y, Brouard, JP, Pousset, JL, Bodo, B (2005) Two cyclopeptides from the seeds of Annona cherimola. Phytochemistry 66: pp. 2376-2380 CrossRef
  41. Wu, TY, Yang, IH, Tsai, YT, Wang, JY, Shiurba, R, Hsieh, TJ, Chang, FR, Chang, WC (2012) Isodesacetyluvaricin, an Annonaceous acetogenin, specifically inhibits gene expression of cyclooxygenase-2. J Nat Prod 75: pp. 572-576 CrossRef
  42. Kaidi, A, Qualtrough, D, Williams, AC, Paraskeva, C (2006) Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66: pp. 6683-6691 CrossRef
  43. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/353/prepub
  
• 刊物主题：Complementary & Alternative Medicine; Internal Medicine; Chiropractic Medicine;
• 出版者：BioMed Central
• ISSN：1472-6882

文摘

Background Angiogenesis, which is initiated by certain tumor micro-environmental conditions and diverse protein factors, plays a pivotal role during tumor development and metastasis. Therefore, many efforts have been made to develop effective anti-angiogenic agents as anticancer therapeutics. In the current study, we investigated the anti-angiogenic potential of an ethanol extract of Annona atemoya seeds (EEAA) in vitro and in vivo. Methods The anti-angiogenic potential of EEAA was evaluated using various in vitro/in vivo models, including cell proliferation, migration, and tube formation by human umbilical vascular endothelial cells (HUVECs); a Matrigel plug assay; and tumor-induced angiogenesis. The expression of hypoxia-inducible factors (HIFs) and vascular endothelial growth factor (VEGF) was investigated using reverse transcription-polymerase chain reaction, immunoassays, and western blotting. Results EEAA was able to significantly inhibit the angiogenic properties of HUVECs in vitro as well as angiogenic factor-induced blood vessel formation in vivo. EEAA down-regulated the expression of VEGF and HIF-1alpha/2alpha at the mRNA and protein levels, respectively, in cancer cells under hypoxic conditions. Conclusions EEAA shows a strong anti-angiogenic potential in both in vitro and in vivo systems, and we suggest that EEAA may be a valuable herbal source for anticancer drug development.